Breaking Down SG&A Expenses: AbbVie Inc. vs Sanofi

A Comparative Analysis of SG&A Expenses: AbbVie Inc. vs. Sanofi

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players like AbbVie Inc. and Sanofi is crucial. Over the past decade, from 2014 to 2023, these giants have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. AbbVie Inc. has seen a significant increase, with expenses peaking in 2022 at approximately 15.3 billion USD, marking a 97% rise from 2016. In contrast, Sanofi's SG&A expenses have remained relatively stable, with a modest increase of around 26% over the same period, reaching their highest in 2023. This divergence highlights AbbVie's aggressive expansion and strategic investments, while Sanofi maintains a steady course. Such insights are invaluable for investors and industry analysts aiming to gauge the financial health and strategic direction of these pharmaceutical leaders.